Geisinger, Indivumed Partner on Personalized Cancer Medicine | GenomeWeb

NEW YORK (GenomeWeb News) – Geisinger Health System today announced a partnership with German firm Indivumed aimed at providing Geisinger's patients access to advanced cancer treatments and clinical trials.

Under the terms of the deal, Indivumed will have access to tissue samples from consenting Geisinger patients for molecular and biochemical profiling. Patients already undergoing a surgical tumor resection will have a portion of the tissue, blood, or urine banked by Geisinger through MyCode, a repository that currently contains 43,000 patient samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."